Related Experiment Video
Updated: Aug 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Treatment of advanced, aggressive non-Hodgkin's lymphoma
1Northwestern University Medical School, Chicago, Illinois.
Abstract:
Although advanced, aggressive non-Hodgkin's lymphoma is highly responsive to chemotherapy, only approximately 30% of patients will have long-term disease-free survival and cure. Complex multiple-drug regimens have been claimed to be superior to standard regimens, eg, cyclophosphamide, doxorubicin, vincristine, and prednisone. However, several studies comparing this regimen with various multiple-drug regimens showed equivalent results with a more favorable toxicity profile for the standard regimen. Central nervous system lymphoma continues to carry a grim prognosis, but new approaches combining chemotherapy with radiation may lead to improved treatment. The availability of hematopoietic growth factors may help determine the role of dose intensity in the treatment of advanced, aggressive non-Hodgkin's lymphoma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Tumor Immunotherapy

